Behcet disease: an undifferentiating and complex vasculitis

References

• Yazici Y, Hatemi G, Bodaghi B, et al. Behçet syndrome. Nat Rev Dis Primers. 2021;7:67.
   PubMed Web of Science ®Google Scholar
• Tong B, Liu X, Xiao J, et al. Immunopathogenesis of Behcet’s disease. Front Immunol. 2019 Mar; 29;(10:665. doi: 10.3389/fimmu.2019.00665. PMID: 30984205; PMCID: PMC6449449
   Web of Science ®Google Scholar
• Yilmaz MA, Ü T. The Immunogenetics of Behcet’s Disease. Adv Exp Med Biol. 2022;1367:335–347. DOI:10.1007/978-3-030-92616-8_12. PMID: 35286701.
   PubMedGoogle Scholar
• Calamia KT, Wilson FC, Icen M, et al. Epidemiology and clinical characteristics of Behçet’s disease in the US: a population-based study. Arthritis Rheum. 2009 May 15;61(5):600–604. PMID: 19405011; PMCID: PMC3024036.
   PubMed Web of Science ®Google Scholar
• Balt J, Jamyanjav B, Jav S, et al. Clinical features of Behcet’s disease in Mongolia: a multicenter study. Clin Rheumatol. 2020 Sep;39(9):2697–2706. Epub 2020 Mar 10. PMID: 32157471.
   PubMed Web of Science ®Google Scholar
• Fernández-Ávila DG, Rincón-Riaño DN, Bernal-Macías S, et al. Prevalence and demographic characteristics of Behcet disease in Colombia: data from the national health registry 2012–2016. Rheumatol Int. 2020 Jan;40(1):17–20. Epub 2019 Oct 29. PMID: 31659428.
   PubMed Web of Science ®Google Scholar
• Thomas T, Chandan JS, Subramanian A, et al. Epidemiology, morbidity and mortal- ity in Behçet’s disease: a cohort study using The Health Improvement Network (THIN).Rheumatology (Oxford. Rheumatology (Oxford, England). 2020;59(10):2785–2795.
   PubMed Web of Science ®Google Scholar
• Hammam N, Li J, Evans M, et al. Epidemiology and treatment of Behçet’s disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Res Ther. 2021 Aug 30;23(1):224. PMID: 34461986; PMCID: PMC8404295.
   PubMed Web of Science ®Google Scholar
• Pakhchanian H, Raiker R, Kardes S. COVID-19 among patients with Behçet syndrome in the United States. Clin Rheumatol. 2022 Jan;41(1):317–319. Epub 2021 Sep 25. PMID: 34562150; PMCID: PMC8475324.
   PubMed Web of Science ®Google Scholar
• Farah S, Al-Shubaili A, Montaser A, et al. Behçet’s syndrome: a report of 41 patients with emphasis on neurological manifestations. J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):382–384. PMID: 9527155; PMCID: PMC2169980.
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behçet’s disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999 Jul;135(1):89–93. PMID: 10393610.
   PubMed Web of Science ®Google Scholar
• Ahn HS, Kim HJ, Kazmi SZ, et al. Familial risk of Behçet’s disease among first-degree relatives: a population-based aggregation study in Korea. Rheumatology (Oxford). 2021 Jun 18;60(6):2697–2705. PMID: 33241295.
   PubMed Web of Science ®Google Scholar
• de Menthon M, Lavalley MP, Maldini C, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009 Oct 15;61(10):1287–1296. PMID: 19790126; PMCID: PMC3867978.
   PubMed Web of Science ®Google Scholar
• Leccese P, Padula MC, Lascaro N, et al. Clinical phenotypes of Behçet’s syndrome in a large cohort of Italian patients: focus on gender differences. Scand J Rheumatol. 2021 Nov;50(6):475–478. Epub 2021 Apr 7. PMID: 33827364.
   PubMed Web of Science ®Google Scholar
• Yazici H, Tüzün Y, Pazarli H, et al. Influence of age of onset and patient’s sex on the prevalence and severity of manifestations of Behçet’s syndrome. Ann Rheum Dis. 1984 Dec;43(6):783–789. PMID: 6524980; PMCID: PMC1001536.
   PubMed Web of Science ®Google Scholar
• Sibley C, Yazici Y, Tascilar K, et al. Behçet syndrome manifestations and activity in the United States versus Turkey – a cross-sectional cohort comparison. J Rheumatol. 2014 Jul;41(7):1379–1384. Epub 2014 Jun 15. PMID: 24931953; PMCID: PMC4565792.
   PubMed Web of Science ®Google Scholar
• Gül A, Uyar FA, Inanc M, et al. Lack of association of HLA-B*51 with a severe disease course in Behçet’s disease. Rheumatology (Oxford). 2001 Jun;40(6):668–672. PMID: 11426025.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003 Jan;82(1):60–76. PMID: 12544711.
   PubMed Web of Science ®Google Scholar
• Daoud F, Rachdi I, Somai M, et al. Epidemiological, clinical, and therapeutic characteristics of Behçet’s disease: a monocentric study in Tunisia. Pan Afr Med J. 2021 Sep 3;40:13. PMID: 34733381; PMCID: PMC8531968.
   PubMed Web of Science ®Google Scholar
• Torgutalp M, Eroglu DS, Sezer S, et al. Patient characteristics in Behçet’s Syndrome and their associations with major organ involvement: a single-centre experience of 2118 cases. Scand J Rheumatol. 2022 Jan;51(1):50–58. Epub 2021 Jun 14. PMID: 34121600.
   PubMed Web of Science ®Google Scholar
• Criteria for diagnosis of Behçet’s disease. International Study Group for Behçet’s Disease. Lancet. 1990 May 5;335(8697):1078–1080. PMID: 1970380.
   PubMed Web of Science ®Google Scholar
• Caruso P, Moretti R. Focus on neuro-Behçet’s disease: a review. Neurol India. 2018 Nov-Dec;66(6):1619–1628. PMID: 30504554.
   PubMed Web of Science ®Google Scholar
• Scherrer MAR, Rocha VB, Garcia LC. Behçet’s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017 Jul-Aug;92(4):452–464. PMID: 28954091; PMCID: PMC5595589.
   PubMed Web of Science ®Google Scholar
• Fei Y, Li X, Lin S, et al. Major vascular involvement in Behçet’s disease: a retrospective study of 796 patients. Clin Rheumatol. 2013 Jun;32(6):845–852. Epub 2013 Feb 27. PMID: 23443336.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Zouboulis CC, Ehrlich GE. Mucocutaneous lesions of Behcet’s disease. Yonsei Med J. 2007 Aug 31;48(4):573–585. PMID: 17722228; PMCID: PMC2628050.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Iwata Y, Asai J, et al. Members of the consensus conference on treatment of skin and mucosal lesions (committee of guideline for the diagnosis and treatment of mucocutaneous lesions of Behçet’s disease). Guidelines for the treatment of skin and mucosal lesions in Behçet’s disease: a secondary publication. J Dermatol. 2020 Mar;47(3):223–235. Epub 2020 Jan 6. PMID: 31907947.
   PubMed Web of Science ®Google Scholar
• Zouboulis CC, Vaiopoulos G, Marcomichelakis N, et al. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades-Behçet’s disease in Greece. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S19–26. PMID: 14727454.
   PubMed Web of Science ®Google Scholar
• Demirkesen C, Tüzüner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behçet syndrome. Am J Clin Pathol. 2001 Sep;116(3):341–346. PMID: 11554161.
   PubMed Web of Science ®Google Scholar
• Valenti S, Gallizzi R, De Vivo D, et al. Intestinal Behçet and Crohn’s disease: two sides of the same coin. Pediatr Rheumatol Online J. 2017 Apr 20;15(1):33. PMID: 28427473; PMCID: PMC5397832.
   PubMed Web of Science ®Google Scholar
• Özdal P Ç. Behçet’s Uveitis: current diagnostic and therapeutic approach. Turk J Ophthalmol. 2020 Jun 27;50(3):169–182. PMID: 32631005; PMCID: PMC7338748.
   PubMedGoogle Scholar
• Matsuo T, Itami M, Nakagawa H, et al. The incidence and pathology of conjunctival ulceration in Behçet’s syndrome. Br J Ophthalmol. 2002 Feb;86(2):140–143. PMID: 11815335; PMCID: PMC1770998.
   PubMed Web of Science ®Google Scholar
• Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Behçet’s disease. Ophthalmology. 2003 Jun;110(6):1137–1141. PMID: 12799237.
   PubMed Web of Science ®Google Scholar
• Kim MK, Kwon HC, Song JJ, et al. Antineutrophil cytoplasmic antibody positivity is associated with vascular involvement in behçet’s disease. Yonsei Med J. 2021 Feb;62(2):149–158. PMID: 33527794; PMCID: PMC7859684.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med. 2004 Dec 1;117(11):867–870. PMID: 15589493.
   PubMed Web of Science ®Google Scholar
• Yazgan Ç, Ertürk H, Taskin A. Imaging features of thoracic manifestations of Behçet’s disease: beyond pulmonary artery involvement. Curr Med Imaging. 2021;17(8):996–1002. PMID: 33438546; PMCID: PMC8653419
   PubMed Web of Science ®Google Scholar
• Toledo-Samaniego N, Oblitas CM, Peñaloza-Martínez E, et al. Arterial and venous involvement in Behçet’s syndrome: a narrative review. J Thromb Thrombolysis. 2022 Feb 19;54(1):162–171. Epub ahead of print. PMID: 35182310.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012 Jan;91(1):35–48. PMID: 22210555.
   PubMed Web of Science ®Google Scholar
• Tazi Mezalek Z, Khibri H, Chadli S, et al. Vascular complications of Behçet disease. Minerva Med. 2021 Dec;112(6):767–778. PMID: 35168306.
   PubMed Web of Science ®Google Scholar
• Sayeed FZ, Nashit M, Bhatty S, et al. A case report of behcet’s disease with thromboses in the superior vena cava and external iliac vein. Cureus. 2022 Apr 12;14(4):e24064. PMID: 35573561; PMCID: PMC9097467.
   PubMed Web of Science ®Google Scholar
• Oumerzouk J, Klevor R, Slioui B, et al. Cerebral venous thrombosis in Behcet’s disease. A report on 24 cases. Rev Neurol (Paris). 2022 Mar;178(3):213–218. Epub 2021 Sep 23. PMID: 34563378.
   PubMed Web of Science ®Google Scholar
• Espinosa G, Font J, Tàssies D, et al. Vascular involvement in Behçet’s disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002 Jan;112(1):37–43. PMID: 11812405.
   PubMed Web of Science ®Google Scholar
• Emmi G, Bettiol A, Silvestri E, et al. Vascular Behçet’s syndrome: an update. Intern Emerg Med. 2019 Aug;14(5):645–652. Epub 2018 Nov 29. PMID: 30499073.
   PubMed Web of Science ®Google Scholar
• Torgutalp M, Sahin Eroglu D, Sezer S, et al. Analysis of vascular involvement in 460 patients with Behçet’s syndrome: clinical characteristics and associated factors. Joint Bone Spine. 2022 Mar;89(2):105277. Epub 2021 Sep 15. PMID: 34536626.
   PubMed Web of Science ®Google Scholar
• Toledo-Samaniego N, Galeano-Valle F, Pinilla-Llorente B, et al. Clinical features and management of venous thromboembolism in patients with Behçet’s syndrome: a single-center case-control study. Intern Emerg Med. 2020 Jun;15(4):635–644. Epub 2019 Dec 4. PMID: 31802406.
   PubMed Web of Science ®Google Scholar
• Hamid M, Adan K, Satte A, et al. Chorea in Neuro-Behçet’s Disease. Cureus. 2021 Oct 25;13(10):e19039. PMID: 34853756; PMCID: PMC8608035.
   PubMedGoogle Scholar
• Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999 Nov;122(Pt 11):2171–2182. PMID: 10545401.
   PubMed Web of Science ®Google Scholar
• Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol. 2014 Sep;261(9):1662–1676. Epub 2013 Dec 24. PMID: 24366648; PMCID: PMC4155170.
   PubMed Web of Science ®Google Scholar
• Duygulu F, Evereklioglu C, Calis M, et al. Synovial nitric oxide concentrations are increased and correlated with serum levels in patients with active Behçet’s disease: a pilot study. Clin Rheumatol. 2005 Aug;24(4):324–330. Epub 2005 May 18. PMID: 15902528.
   PubMed Web of Science ®Google Scholar
• Kim HA, Choi KW, Song YW. Arthropathy in Behçet’s disease. Scand J Rheumatol. 1997;26(2):125–129. PMID: 9137328.
   PubMed Web of Science ®Google Scholar
• Tono T, Kikuchi H, Sawada T, et al. Clinical features of Behçet’s disease patients with joint symptoms in japan: a national multicenter study. Mod Rheumatol. 2021 Nov 29;roab092. doi:10.1093/mr/roab092. Epub ahead of print. PMID: 34850090
   Web of Science ®Google Scholar
• Ye JF, Hou CC, Bao HF, et al. New insight into the features of Behçet’s disease with gastrointestinal ulcer: a cross-sectional observational study. Orphanet J Rare Dis. 2021 Oct 21;16(1):444. PMID: 34674734; PMCID: PMC8532303.
   PubMed Web of Science ®Google Scholar
• Kim DH, Cheon JH. Intestinal Behçet’s disease: a true inflammatory bowel disease or merely an intestinal complication of systemic vasculitis? Yonsei Med J. 2016 Jan;57(1):22–32. PMID: 26632379; PMCID: PMC4696957.
   PubMed Web of Science ®Google Scholar
• Ye JF, Guan JL. Differentiation between intestinal Behçet’s disease and Crohn’sdisease based on endoscopy. Turk J Med Sci. 2019 Feb 11;49(1):42–49. PMID: 30761850; PMCID: PMC7350800.
   PubMed Web of Science ®Google Scholar
• Goloeva RG, Alekberova ZS, Lisitsyna TA, et al. Intestinal manifestations of Behçet’s disease. Ter Arkh. 2019 May 15;91(5):111–119. Russian. PMID: 32598685.
   PubMed Web of Science ®Google Scholar
• Hou CC, Ye JF, Ma HF, et al. Clinical characteristics and risk factors of intestinal involvement in Behçet’s syndrome patients: a cross-sectional study from a single center. Orphanet J Rare Dis. 2021 Mar 17;16(1):132. PMID: 33731182; PMCID: PMC7972242.
   PubMed Web of Science ®Google Scholar
• Geri G, Wechsler B, Thi Huong DL, et al. Spectrum of cardiac lesions in Behçet disease: a series of 52 patients and review of the literature. Medicine (Baltimore). 2012 Jan;91(1):25–34. PMID: 22198500.
   PubMed Web of Science ®Google Scholar
• Mazzoni C, Scheggi V, Mariani T. Cardiac involvement in Behçet disease presenting as non-bacterial thrombotic endocarditis: a case report. J Cardiol Cases. 2021 Apr 7;24(4):157–160. PMID: 35059048; PMCID: PMC8758554.
   PubMedGoogle Scholar
• Briosa A, Gomes AC, CastelBranco A, et al. Behçet’s disease: a case report about a rare cause of intra-cardiac mass. Eur Heart J Case Rep. 2021 Oct 8;5(10):ytab299. PMID: 34632262; PMCID: PMC8497885.
   PubMedGoogle Scholar
• Demirelli S, Degirmenci H, Inci S, et al. Cardiac manifestations in Behcet’s disease. Intractable Rare Dis Res. 2015 May;4(2):70–75. PMID: 25984424; PMCID: PMC4428189.
   PubMed Web of Science ®Google Scholar
• Shadmanfar S, Masoumi M, Davatchi F, et al. Cardiac manifestations in Iranian patients with Behçet’s Disease. J Tehran Heart Cent. 2021 Jul;16(3):109–112. PMID: 35633822; PMCID: PMC9108474.
   PubMedGoogle Scholar
• Ramoglu MG, Atalay S, Uçar T, et al. Multiple intra-cardiac masses: a life-threatening complication of Behçet’s disease. Echocardiography. 2020 Jul;37(7):1077–1079. Epub 2020 Jun 17. PMID: 32557850.
   PubMed Web of Science ®Google Scholar
• Yildirim R, Dinler M, Bilge NSY, et al. A rarely seen manifestation in Behcet’s disease: intracardiac thrombosis. Clin Rheumatol. 2021 Oct;40(10):4355–4356. Epub 2021 Mar 30. PMID: 33783633.
   PubMed Web of Science ®Google Scholar
• Abreu L, Marmelo B, Gil J, et al. Double coronary thrombosis in a patient with Behçet’s disease. Rev Port Cardiol (Engl Ed). 2020 Jul;39(7):407.e1–407.e4. English, Portuguese. Epub 2020 Jul 14. PMID: 32674919.
   PubMed Web of Science ®Google Scholar
• Farhat SB, Slim M. A coronary artery aneurysm revealing a Behçet’s disease: a case report. Pan Afr Med J. 2020 May 4;36:3. PMID: 32550966; PMCID: PMC7282617.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Tharwat S, Batouty NM, et al. Cardiac magnetic resonance imaging in patients with Behçet’s disease. Adv Rheumatol. 2021 Dec 7;61(1):74. PMID: 34876236.
   PubMedGoogle Scholar
• Altiparmak MR, Tanverdi M, Pamuk ON, et al. Glomerulonephritis in Behçet’s disease: report of seven cases and review of the literature. Clin Rheumatol. 2002 Feb;21(1):14–18. PMID: 11954877.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Karaaslan H, Ugurlu S, et al. Fever in Behçet’s syndrome. Clin Exp Rheumatol. 2013 May-Jun;31(3 Suppl 77):64–67. Epub 2013 Sep 9. PMID: 24064017.
   PubMed Web of Science ®Google Scholar
• Akpolat T, Diri B, Oguz Y, et al. Behçet’s disease and renal failure. Nephrol Dial Transplant. 2003 May;18(5):888–891. PMID: 12686660.
   PubMed Web of Science ®Google Scholar
• Yolbas S, Yildirim A, Gozel N, et al. Hematological indices may be useful in the diagnosis of systemic lupus erythematosus and in determining disease activity in Behçet’s disease. Med Princ Pract. 2016;25(6):510–516. Epub 2016 Jun 24. PMID: 27348861; PMCID: PMC5588503.
   PubMed Web of Science ®Google Scholar
• Koba S, Sekioka T, Takeda S, et al. Acute monocytic leukemia masquerading behçet’s disease-like illness at onset in an elderly female. Case Rep Hematol. 2016;2016:4231276. DOI:10.1155/2016/4231276. Epub 2016 Aug 16. PMID: 27610252; PMCID: PMC5004031.
   PubMedGoogle Scholar
• Atas U, Tazegul G, Yucel O, et al. Behçet’s disease and T-cell large granular lymphocytic leukemia: two case reports and a hypothesis on a common pathogenesis. Turk J Immunol. 2020;8(2):94–99. Epub 2020 Jul 27.
   Web of Science ®Google Scholar
• Asano T, Sato S, Furuya MY, et al. Intestinal Behçet disease associated with myelodysplastic syndrome accompanying trisomy 8 successfully treated with abdominal surgery followed by hematopoietic stem cell transplantation: a case report. Medicine (Baltimore). 2019 Nov;98(46):e17979. PMID: 31725663; PMCID: PMC6867715.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Sato S, Suzuki T, et al. Intestinal Behçet’s disease complicated by myelodysplastic syndrome and secondary pulmonary alveolar proteinosis: a case report. BMC Gastroenterol. 2021 Dec 20;21(1):488. PMID: 34930121; PMCID: PMC8686569.
   PubMed Web of Science ®Google Scholar
• Mattioli I, Bettiol A, Silvestri E, et al. Prevalence and clinical course of SARS-CoV-2 infection in patients with Behçet’s syndrome. Clin Exp Rheumatol. 2021 Sep-Oct 39;132(5):47–50. Epub 2021 Jun 9. PMID: 34128795.
   Google Scholar
• Elmas ÖF, Demirbas A, Bagcier F, et al. Treatment considerations for Behçet disease in the era of COVID-19: a narrative review. Dermatol Ther. 2021 Jan;34(1):e14507. Epub 2020 Nov 9. PMID: 33150651.
   PubMed Web of Science ®Google Scholar
• Adil A, Goyal A, Quint JM. Behcet disease. 2022 Feb 10; StatPearls. Treasure Island (FL): StatPearls Publishing. Internet]. 2022 Jan. PMID: 29262080. Internet].
   Google Scholar
• Davatchi F. Diagnosis/classification criteria for Behcet’s disease. Patholog Res Int. 2012;2012:607921. DOI:10.1155/2012/607921. Epub 2011 Sep 27. PMID: 21961081; PMCID: PMC3180812.
   PubMedGoogle Scholar
• Davatchi F, Assaad-Khalil S, Calamia KT; International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):338–347. Epub 2013 Feb 26. PMID: 23441863.
   PubMed Web of Science ®Google Scholar
• Blake T, Pickup L, Carruthers D, et al. Birmingham Behçet’s service: classification of disease and application of the 2014 International Criteria for Behçet’s Disease (ICBD) to a UK cohort. BMC Musculoskelet Disord. 2017 Mar 11;18(1):101. PMID: 28283043; PMCID: PMC5346254.
   PubMed Web of Science ®Google Scholar
• Oh SH, Han EC, Lee JH, et al. Comparison of the clinical features of recurrent aphthous stomatitis and Behçet’s disease. Clin Exp Dermatol. 2009;34(6):e208–e212.
   PubMed Web of Science ®Google Scholar
• Temiz SA, Balevi S, Oltulu P, et al. Histopathological comparison of pathergy positive and negative areas of newly diagnosed Behçet patients. Int J Clin Pract. 2021 Dec;75(12):e14994. Epub 2021 Nov 6. PMID: 34710265.
   PubMed Web of Science ®Google Scholar
• Ciscato A, Sadeghi S, Speziale A, et al. Behcet’s disease mimicking Crohn’s disease: a diagnostic pitfall in GI tract biopsies. Int J Surg Pathol. 2022 Jul 27;10668969221113477. doi:10.1177/10668969221113477. Epub ahead of print. PMID: 35898181
   Web of Science ®Google Scholar
• Nonaka D, Takase H, Machii M, et al. Colchicine therapy for deep vein thrombosis in a patient with vascular-type Behçet disease: a case report. Medicine (Baltimore). 2020 Apr;99(16):e19814. PMID: 32312000; PMCID: PMC7220338.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Wang H, Schwartz DM, et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat Genet. 2016 Jan;48(1):67–73. Epub 2015 Dec 7. PMID: 26642243; PMCID: PMC4777523.
   PubMed Web of Science ®Google Scholar
• Mizuki N, Meguro A, Tohnai I, et al. Association of major histocompatibility complex class I chain-related gene A and HLA-B alleles with Behçet’s disease in Turkey. Jpn J Ophthalmol. 2007 Nov-Dec;51(6):431–436. Epub 2007 Dec 21. PMID: 18158593.
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Stübiger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Behçet’s disease in patients of German and Turkish origin. Tissue Antigens. 2001 Sep;58(3):166–170. PMID: 11703824.
   PubMedGoogle Scholar
• Salvarani C, Boiardi L, Mantovani V, et al. Association of MICA alleles and HLA-B51 in Italian patients with Behçet’s disease. J Rheumatol. 2001 Aug;28(8):1867–1870. PMID: 11508592.
   PubMed Web of Science ®Google Scholar
• Leccese P, Alpsoy E. Behçet’s Disease: an overview of etiopathogenesis. Front Immunol. 2019 May 10;10:1067. PMID: 31134098; PMCID: PMC6523006.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Seyahi E, Fresko I, et al. One year in review 2021: behçet’s syndrome. Clin Exp Rheumatol. 2021 Sep-Oct 39;132(5):3–13. Epub 2021 Sep 14. PMID: 34524077.
   Google Scholar
• Wei F, Zhang YU, Li W. A meta-analysis of the association between Behçet’s disease and MICA-A6. Biomed Rep. 2016 Jun;4(6):741–745. Epub 2016 Mar 31. PMID: 27284416; PMCID: PMC4887777.
   PubMedGoogle Scholar
• Lee YH, Song GG. Associations between major histocompatibility complex class I chain-related gene A polymorphisms and susceptibility to Behcet’s disease. A meta-analysis. Z Rheumatol. 2015 Oct;74(8):714–721. PMID: 26184953.
   PubMed Web of Science ®Google Scholar
• Galeone M, Colucci R, D’Erme AM, et al. Potential infectious etiology of Behçet’s disease. Patholog Res Int. 2012;2012:595380. DOI:10.1155/2012/595380. Epub 2011 Dec 29. PMID: 22254152; PMCID: PMC3255303.
   PubMedGoogle Scholar
• Mumcu G, Inanc N, Aydin SZ, et al. Association of salivary S. mutans colonisation and mannose-binding lectin deficiency with gender in Behçet’s disease. Clin Exp Rheumatol. 2009 Mar-Apr;27(2 Suppl 53):S32–6. PMID: 19796530.
   PubMed Web of Science ®Google Scholar
• Seoudi N, Bergmeier LA, Drobniewski F, et al. The oral mucosal and salivary microbial community of Behçet’s syndrome and recurrent aphthous stomatitis. J Oral Microbiol. 2015 Jun;7(1):27150. PMID: 26037240; PMCID: PMC4452653.
   PubMed Web of Science ®Google Scholar
• Safi R, Kallas R, Bardawil T, et al. Neutrophils contribute to vasculitis by increased release of neutrophil extracellular traps in Behçet’s disease. J Dermatol Sci. 2018 Nov;92(2):143–150. Epub 2018 Aug 31. PMID: 30237006.
   PubMed Web of Science ®Google Scholar
• Le Joncour A, Martos R, Loyau S, et al. Critical role of neutrophil extracellular traps (NETs) in patients with Behcet’s disease. Ann Rheum Dis. 2019 Sep;78(9):1274–1282. Epub 2019 May 30. PMID: 31147357.
   PubMed Web of Science ®Google Scholar
• Bettiol A, Becatti M, Silvestri E, et al. Neutrophil-mediated mechanisms of damage and in-vitro protective effect of colchicine in non-vascular Behçet’s syndrome. Clin Exp Immunol. 2021 Dec;206(3):410–421. Epub 2021 Oct 8. PMID: 34562315; PMCID: PMC8561698.
   PubMed Web of Science ®Google Scholar
• Yavuz S, Akdeniz T, Hancer V, et al. Dual effects of testosterone in Behcet’s disease: implications for a role in disease pathogenesis. Genes Immun. 2016 Sep;17(6):335–341. Epub 2016 Jul 28. PMID: 27467286.
   PubMed Web of Science ®Google Scholar
• Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behçet’s disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31(4):205–210. PMID: 12369651.
   PubMed Web of Science ®Google Scholar
• Ben Ahmed M, Houman H, Miled M, et al. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet’s disease. Arthritis Rheum. 2004 Jul;50(7):2291–2295. PMID: 15248229.
   PubMed Web of Science ®Google Scholar
• Singh RP, Hasan S, Sharma S, et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014 Dec;13(12):1174–1181. Epub 2014 Aug 23. PMID: 25151974.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol. 2007 Sep;8(9):967–974. Epub 2007 Jun 20. PMID: 17581537.
   PubMed Web of Science ®Google Scholar
• Liu X, Yang P, Wang C, et al. IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease. Rheumatology (Oxford). 2011 Feb;50(2):293–298. Epub 2010 Nov 8. PMID: 21059671.
   PubMed Web of Science ®Google Scholar
• Wakefield D, Lloyd A. The role of cytokines in the pathogenesis of inflammatory eye disease. Cytokine. 1992 Jan;4(1):1–5. PMID: 1617154.
   PubMed Web of Science ®Google Scholar
• Butta NV, Fernández-Bello I, López-Longo FJ, et al. Endothelial dysfunction and altered coagulation as mediators of thromboembolism in Behçet disease. Semin Thromb Hemost. 2015 Sep;41(6):621–628. Epub 2015 Aug 15. PMID: 26276934.
   PubMed Web of Science ®Google Scholar
• Sancak B, Onder M, Oztas MO, et al. Nitric oxide levels in Behçet’s disease. J Eur Acad Dermatol Venereol. 2003 Jan;17(1):7–9. PMID: 12602959.
   PubMed Web of Science ®Google Scholar
• Taysi S, Sari RA, Dursun H, et al. Evaluation of nitric oxide synthase activity, nitric oxide, and homocysteine levels in patients with active Behcet’s disease. Clin Rheumatol. 2008 Dec;27(12):1529–1534. Epub 2008 Jul 18. PMID: 18636307.
   PubMed Web of Science ®Google Scholar
• La Regina M, Gasparyan AY, Orlandini F, et al. Behçet’s disease as a model of venous thrombosis. Open Cardiovasc Med J. 2010 Feb 23;4:71–77. PMID: 20360979; PMCID: PMC2847254.
   PubMedGoogle Scholar
• Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005 Jun;127(6):2243–2253. PMID: 15947344.
   PubMed Web of Science ®Google Scholar
• Akyol L, Toz B, Ö B, et al. Budd-Chiari syndrome in Behçet’s disease: a retrospective multicenter study. Clin Rheumatol. 2022 Jan;41(1):177–186. Epub 2021 Aug 9. PMID: 34368908.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behçet’s syndrome. Ann Rheum Dis. 2018 Jun;77(6):808–818. Epub 2018 Apr 6. PMID: 29625968.
   PubMed Web of Science ®Google Scholar
• Bozca BC, Alpsoy E. Experimental therapeutic solutions for Behcet’s disease. J Exp Pharmacol. 2021 Feb 12;13:127–145. PMID: 33603502; PMCID: PMC7886245.
   PubMedGoogle Scholar
• Yang S, Huang Z, Liu X, et al. Comparative study of Adalimumab versus conventional therapy in sight-threatening refractory Behçet’s uveitis with vasculitis. Int Immunopharmacol. 2021 Apr; 93:107430. doi: 10.1016/j.intimp.2021.107430. Epub 2021 Feb 10. PMID: 33581500
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Leccese P, Emmi G, et al. Treatment of Behçet’s disease: an algorithmic multidisciplinary approach. Front Med (Lausanne). 2021 Apr 28;8:624795. PMID: 33996847; PMCID: PMC8115406.
   PubMed Web of Science ®Google Scholar
• Alpsoy E, Er H, Durusoy C, et al. The use of sucralfate suspension in the treatment of oral and genital ulceration of Behçet disease: a randomized, placebo-controlled, double-blind study. Arch Dermatol. 1999 May;135(5):529–532. PMID: 10328192.
   PubMedGoogle Scholar
• Chams-Davatchi C, Barikbin B, Shahram F, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double-blind controlled trial. Int J Rheum Dis. 2010 Aug;13(3):253–258. PMID: 20704623.
   PubMed Web of Science ®Google Scholar
• Yurdakul S, Mat C, Tüzün Y, et al. A double-blind trial of colchicine in Behçet’s syndrome. Arthritis Rheum. 2001 Nov;44(11):2686–2692. PMID: 11710724.
   PubMed Web of Science ®Google Scholar
• Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, et al. Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial. Mod Rheumatol. 2009;19(5):542–549. Epub 2009 Jul 14. PMID: 19597921.
   PubMed Web of Science ®Google Scholar
• Pakfetrat A, Mansourian A, Momen-Heravi F, et al. Comparison of colchicine versus prednisolone in recurrent aphthous stomatitis: a double-blind randomized clinical trial. Clin Invest Med. 2010 Jun 1;33(3):E189–95. PMID: 20519098.
   PubMed Web of Science ®Google Scholar
• Takeno M, Dobashi H, Tanaka Y, et al. Apremilast in a Japanese subgroup with Behçet’s syndrome: results from a Phase 3, randomized, double-blind, placebo-controlled study. Mod Rheumatol. 2022 Feb 28;32(2):413–421. PMID: 34894266.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome–a phase 2, placebo-controlled study. N Engl J Med. 2015 Apr 16;372(16):1510–1518. PMID: 25875256.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Behçet’s syndrome. N Engl J Med. 2019 Nov 14;381(20):1918–1928. PMID: 31722152.
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005 Jan;32(1):98–105. PMID: 15630733.
   PubMed Web of Science ®Google Scholar
• Tian Z, Gershwin ME, Zhang C. Regulatory NK cells in autoimmune disease. J Autoimmun. 2012 Sep;39(3):206–215. Epub 2012 Jun 15. PMID: 22704425.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet’s syndrome: effects on long-term prognosis. Arthritis Rheum. 1997 Apr;40(4):769–774. PMID: 9125262.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014 Mar;121(3):785–96.e3. Epub 2013 Dec 17. PMID: 24359625.
   PubMed Web of Science ®Google Scholar
• Bennji SM, du Preez L, Griffith-Richards S, et al. Recurrent pulmonary aneurysms: hughes-stovin syndrome on the spectrum of Behçet disease. Chest. 2017 Nov;152(5):e99–e103. PMID: 29126538.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of Adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017 Jan;36(1):183–189. Epub 2016 Nov 16. PMID: 27853889.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of Adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011 Jul-Aug;29(4 Suppl 67):S54–7. Epub 2011 Sep 27. PMID: 21968237.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015 Aug; 62:67–74. doi: 10.1016/j.jaut.2015.06.005. Epub 2015 Jul 8. PMID: 26162757
   PubMed Web of Science ®Google Scholar
• Kötter I, Günaydin I, Zierhut M, et al. The use of interferon alpha in Behçet disease: review of the literature. Semin Arthritis Rheum. 2004 Apr;33(5):320–335. PMID: 15079763.
   PubMed Web of Science ®Google Scholar
• Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behçet’s disease. Lancet. 1989 May 20;1(8647):1093–1096. PMID: 2566048.
   PubMed Web of Science ®Google Scholar
• Park YE, Cheon JH. Updated treatment strategies for intestinal Behçet’s disease. Korean J Intern Med. 2018 Jan;33(1):1–19. Epub 2017 Dec 8. PMID: 29207867; PMCID: PMC5768550.
   PubMed Web of Science ®Google Scholar
• Hatemi I, Esatoglu SN, Hatemi G, et al. Characteristics, treatment, and long-term outcome of gastrointestinal involvement in Behcet’s syndrome: a strobe-compliant observational study from a dedicated multidisciplinary center. Medicine (Baltimore). 2016 Apr;95(16):e3348. PMID: 27100417; PMCID: PMC4845821.
   PubMed Web of Science ®Google Scholar
• Jung YS, Cheon JH, Hong SP, et al. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet’s disease. Inflamm Bowel Dis. 2012 Apr;18(4):750–757. Epub 2011 May 25. PMID: 21618352.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medication. Intern Med. 2013;52(17):1855–1862. PMID: 23994973.
   PubMed Web of Science ®Google Scholar
• Travis SP, Czajkowski M, McGovern DP, et al. Treatment of intestinal Behçet’s syndrome with chimeric tumour necrosis factor alpha antibody. Gut. 2001 Nov;49(5):725–728. PMID: 11600479; PMCID: PMC1728519.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Ma C, Dong R, et al. Efficacy and safety of anti-tumor necrosis factor-alpha agents for patients with intestinal behcet’s disease: a systematic review and meta-analysis. Yonsei Med J. 2022 Feb;63(2):148–157. PMID: 35083900; PMCID: PMC8819411.
   PubMedGoogle Scholar
• Arbrile M, Radin M, Rossi D, et al. Vedolizumab for the management of refractory Behçet’s disease: from a case report to new pieces of mosaic in a complex disease. Front Immunol. 2021 Oct 25;12:769785. PMID: 34759935; PMCID: PMC8573273.
   PubMed Web of Science ®Google Scholar
• Zhong H, Liu T, Liu Y, et al. Efficacy and safety of tocilizumab in Behçet’s syndrome with refractory arterial lesions: a single-centre observational cohort study in China. Rheumatology (Oxford). 2022 Jul 6;61(7):2923–2930. PMID: 34791076; PMCID: PMC9258597.
   PubMed Web of Science ®Google Scholar
• Tuzun H, Seyahi E, Arslan C, et al. Management and prognosis of nonpulmonary large arterial disease in patients with Behçet disease. J Vasc Surg. 2012 Jan;55(1):157–163. Epub 2011 Sep 23. PMID: 21944910.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Wechsler B, Resche-Rigon M, et al. Immunosuppressants reduce venous thrombosis relapse in Behçet’s disease. Arthritis Rheum. 2012 Aug;64(8):2753–2760. PMID: 22354392.
   PubMed Web of Science ®Google Scholar
• Emmi G, Vitale A, Silvestri E, et al. Adalimumab-based treatment versus disease-modifying antirheumatic drugs for venous thrombosis in Behçet’s syndrome: a retrospective study of seventy patients with vascular involvement. Arthritis Rheumatol. 2018 Sep;70(9):1500–1507. Epub 2018 Jul 19. PMID: 29676522.
   PubMed Web of Science ®Google Scholar
• Yalcin Kehribar D, Gunaydin S, Ozgen M. Infliximab therapy in parenchymal neuro-Behçet’s disease: a single-center experience. Int J Rheum Dis. 2021 Oct;24(10):1302–1307. Epub 2021 Aug 24. PMID: 34427044.
   PubMed Web of Science ®Google Scholar
• Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016 Jul 8;3(5):e258. PMID: 27458602; PMCID: PMC4950829.
   PubMed Web of Science ®Google Scholar
• Lockwood CM, Hale G, Waldman H, et al. Remission induction in Behçet’s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003 Dec;42(12):1539–1544. Epub 2003 Aug 29. PMID: 12949252.
   PubMed Web of Science ®Google Scholar
• Mohammad AJ, Smith RM, Chow YW, et al. Alemtuzumab as remission induction therapy in Behçet disease: a 20-year experience. J Rheumatol. 2015 Oct;42(10):1906–1913. Epub 2015 Aug 15. PMID: 26276966.
   PubMed Web of Science ®Google Scholar
• Cantarini L, Vitale A, Scalini P, et al. Anakinra treatment in drug-resistant Behcet’s disease: a case series. Clin Rheumatol. 2015 Jul;34(7):1293–1301. Epub 2013 Dec 5. PMID: 24305945.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Rigante D, et al. The presence of uveitis is associated with a sustained response to the Interleukin (IL)-1 inhibitors anakinra and canakinumab in Behçet’s Disease. Ocul Immunol Inflamm. 2020;28(2):298–304. Epub 2018 Aug 27. PMID: 30148652.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al.
   Google Scholar
• Fabiani C, Vitale A, Emmi G. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017 Jan;36(1):191–197. Epub 2016 Dec 16. PMID: 27981463.
   PubMed Web of Science ®Google Scholar
• Md T-TI, Md KS, Md KM, et al. Gül A Md. safety and efficacy of gevokizumab in patients with Behçet’s disease uveitis: results of an exploratory phase 2 study. Ocul Immunol Inflamm. 2017 Feb;25(1):62–70. Epub 2016 Jan 30. Erratum in: Ocul Immunol Inflamm. 2017 Aug;25(4):587. PMID: 26829647
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Pavesio C, De Cordoue A, et al. Use of gevokizumab in patients with behçet’s disease uveitis: an international, randomized, double-masked, placebo-controlled study and open-label extension study. Ocul Immunol Inflamm. 2018;26(7):1023–1033. Epub 2018 Jan 25. PMID: 29370572.
   PubMed Web of Science ®Google Scholar
• Di Scala G, Bettiol A, Cojan RD, et al. Efficacy of the anti-IL 17 secukinumab in refractory Behçet’s syndrome: a preliminary study. J Autoimmun. 2019 Feb; 97:108–113. doi: 10.1016/j.jaut.2018.09.002. Epub 2018 Sep 11. PMID: 30213443
   PubMed Web of Science ®Google Scholar
• Fagni F, Bettiol A, Talarico R, et al. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study. Ann Rheum Dis. 2020 Aug;79(8):1098–1104. Epub 2020 May 7. PMID: 32381569.
   PubMed Web of Science ®Google Scholar
• Dincses E, Yurttas B, Esatoglu SN, et al. Secukinumab induced Behçet’s syndrome: a report of two cases. Oxf Med Case Reports. 2019 May 31;2019(5):omz041. PMID: 31198577; PMCID: PMC6544425.
   PubMed Web of Science ®Google Scholar